{
    "organizations": [],
    "uuid": "4045e730b2ec04b9aaf16fc7930826cee79b066d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-tg-therapeutics-jiangsu-hengrui-an/brief-tg-therapeutics-jiangsu-hengrui-announce-agreement-for-btk-inhibitor-program-for-treatment-of-hematologic-malignancies-idUSFWN1P30KD",
    "ord_in_thread": 0,
    "title": "BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 45 PM / Updated 9 minutes ago BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies Reuters Staff 1 Min Read \nJan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd : \n* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES \n* TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​ \n* TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​  ",
    "published": "2018-01-08T14:43:00.000+02:00",
    "crawled": "2018-01-08T15:00:42.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "jiangsu",
        "hengrui",
        "announce",
        "agreement",
        "btk",
        "inhibitor",
        "program",
        "treatment",
        "hematologic",
        "malignancy",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "jiangsu",
        "hengrui",
        "medicine",
        "co",
        "ltd",
        "tg",
        "therapeutic",
        "jiangsu",
        "hengrui",
        "medicine",
        "announce",
        "global",
        "license",
        "agreement",
        "development",
        "commercialization",
        "novel",
        "btk",
        "inhibitor",
        "program",
        "treatment",
        "hematologic",
        "malignancy",
        "tg",
        "therapeutic",
        "inc",
        "term",
        "hengrui",
        "receive",
        "licensing",
        "fee",
        "milestone",
        "payable",
        "tg",
        "common",
        "tg",
        "therapeutic",
        "inc",
        "eligible",
        "receive",
        "collaboration",
        "licensing",
        "payment",
        "million",
        "addition",
        "royalty",
        "future"
    ]
}